ClinicalTrials.gg
RecruitingNCT06864897RSA-10Updated Mar 14, 2025

The 10-year Follow-up of the Delta-TT Trial.

An observational study in Hip Dislocation, sponsored by JointResearch. Recruiting at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by JointResearch · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
51
Sex
All
01

Study summary

This 10-year follow-up study aims to further investigate long-term migration patterns of the uncemented Delta-TT cup and H-MAX S stem, comparing outcomes between ceramic and polyethylene liners. Given the predictive value of early RSA migration patterns at the 2-year mark for identifying implants at risk of aseptic loosening, we hypothesize that the Delta-TT cup will demonstrate good stability at the 10-year postoperative mark. Besides, it is hypothesized that migration of Delta TT-cups is comparable between ceramic and polyethylene liners.

The primary objective of this study is to measure the long-term stability of the Delta TT cup, combined with either a ceramic or cross-linked polyethylene liner, by means of RSA at 10-years postoperatively.

Secondary objectives are to measure long-term stability of the H-MAX S stem, by means of RSA at 10-year postoperatively. Furthermore the study aims to measure implant survival rates and patient-reported outcomes for both the Delta-TT cup and H-MAX S stem, comparing outcomes between the ceramic and polyethylene group.

02

Conditions studied

  • Hip Dislocation

Browse trials for

03

In context

Hip Dislocation

107 studies on the registry are indexed under Hip Dislocation; 36 are open to participants now.

This study's planned enrollment of 51 is below the median of 120 across 39 observational studies indexed under Hip Dislocation.

Browse Hip Dislocation studies →

Lead sponsor

JointResearch is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients enrolled in the initial Delta-TT trial are eligible for inclusion. These patients recieved a hip prothesis including a Delta-TT cup, a H-MAX S Stem and either a polyethylene or a ceramic Liner.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in the initial Delta-TT trial

Exclusion criteria

Exclusion Criteria:

  • Patient is unable or unwilling to sign the specific to this study.
  • Patient is unsuitable for participation in the study based on the investigator's judgement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
51 participants (estimated)
Patient registry
No

Groups and cohorts

  • Polyethylene liner

    Device: Total hip prosthesis

  • Ceramic liner

    Device: Total hip prothesis

Interventions

  • DeviceTotal hip prothesis

    Total hip prothesis with a Delta-TT cup, H MAX S Stem and a ceramic liner

  • DeviceTotal hip prosthesis

    Total hip prosthesis with a Delta TT cup, H MAX S stem and polyethylene liner

06

What researchers measure

Primary outcomes

  1. Long-term (10-year) migration pattern of the Delta-TT cup compared between a ceramic and polyethylene liner.

    Measured in 3D translations and rotations by means of Radiostereometric X-ray images at 10-years postoperatively. Data will be summarized by treatment group. A mixed model analysis will be performed to assess cup migration, with liner type (polyethylene vs. ceramic) as the primary independent value. The primary outcome is the effect of the liner type on implant migration. Differences are considered significant for p-values below 0.05.

    Time frame: 10 Years

Secondary outcomes

  1. Long-term (10-year) migration pattern of the H-MAX S Stem compared between a ceramic and polyethylene liner.

    Measured in 3D translations and rotations by means of Radiostereometric X-ray images at 10-years postoperatively. Data will be summarized by treatment group. A mixed model analysis will be performed to assess stem migration, with liner type (polyethylene vs. ceramic) as the primary independent value. The primary outcome is the effect of the liner type on implant migration. Differences are considered significant for p-values below 0.05.

    Time frame: 10 years

  2. Implant survival of the Delta TT cup and H-MAX S stem.

    Survival data will be collected from the Dutch Arthroplasty Register (LROI). The collected data includes: revision (yes/no), Reason for revision and survival in years. Differences in revision rates will be reported, but nog statistically tested since the study is not powered for survival analysis.

    Time frame: 10 years

  3. Radiographic signs of osteolysis around the Delta-TT cup.

    Radiolucent lines are examined on lateral and anteroposterior X-rays. A radiolucent line is defined as such if the maximum width is equal to or greater than 1 mm. Orthopeadic surgeons will assess the radiolucent lines and will be blinded for liner type (obscured by researcher). Radiolucent lines are assessed in the three acetabular zones defined by DeLee and Charnley. A Chi-square test is used to compare the numer of cases with one or more radiolucent lines between the polyethylene liner group and the ceramix liner group. If there are fewer than 10 observed cases with one or more radiolucent lines in one of the two groups, the Fisher's exact test is used, which is valid for all sample sizes.

    Time frame: 10 years

  4. Radiographic signs of osteolysis around the H-Max S stem.

    Radiolucent lines are examined on lateral and anteroposterior X-rays. A radiolucent line is defined as such if the maximum width is equal to or greater than 1 mm. Orthopeadic surgeons will assess the radiolucent lines and will be blinded for liner type (obscured by researcher). Radiolucent lines are assessed in the seven zones zones defined by Gruen. A Chi-square test is used to compare the numer of cases with one or more radiolucent lines between the polyethylene liner group and the ceramix liner group. If there are fewer than 10 observed cases with one or more radiolucent lines in one of the two groups, the Fisher's exact test is used, which is valid for all sample sizes.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for May 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 7, 2025
StartActual
Oct 10, 2024
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2029
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06864897
Lead sponsor
JointResearch
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Oct 10, 2024
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Mar 14, 2025

Study contacts

Amdanda Klaassen, Msc
Contact
A.D.Klaassen@olvg.nl
+3120 599 3653
Okke Hoonhout
Contact
o.hoonhout@olvg.nl
+3120 599 3653
Rudolf Poolman, PhD
principal investigator · Orthopedic Surgeon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion